Overview
- For 2025, Labcorp reported more than 7% revenue growth, roughly 13% adjusted EPS growth, margin expansion, and Q4 results of $3.5 billion in revenue with adjusted EPS of $4.07, up 18% year over year.
- 2026 guidance calls for 4.7%–6% revenue growth, adjusted EPS of $17.65–$18.25, free cash flow of $1.24–$1.36 billion, and higher capital spending of about 4% of revenue to build a new 500,000‑square‑foot central lab and kit facility.
- Management expects broader margin gains in Biopharma Laboratory Services in 2026, supported by Central Lab growth and the completion of Early Development streamlining by Q2 after pruning about $50 million of lower‑utilization work.
- Esoteric and specialty testing grew at double‑digit rates in 2025, with esoteric testing rising to 41.5% of testing revenue in Q4 2025 from 37.5% in Q1 2023.
- The company signed or closed 13 deals and highlighted recent transactions with Parkview Health, Community Health Systems, Incyte Diagnostics, and Empire City Laboratories, noting more than $1 billion in revenue added over three years.